Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and ...

The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...

免预处理，一月几乎完全清除致病细胞，CAR-T治疗自免疾病结果亮眼Cabaletta Bio近日公布其RESET-PV临床试验的初步数据。该试验旨在评估其在研自体CAR-T细胞疗法rese-cel（resecabtagene ...

The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell ...

BCMA-targeting CAR T-cell therapy shows similar efficacy and safety for REMPs and non-REMPs, despite access disparities. REMPs experience reduced access to CAR T therapy, with significant drops in ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital ...

This report provides a comprehensive analysis of the global CAR-T cell therapy isolator Market, highlighting growth trends, regional dynamics, and key industry drivers. It is published by Towards ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

October 12, 2025 - PORTERVILLE, Calif. — A cutting-edge cancer treatment that reprograms the body’s own immune cells saved a Porterville child’s life — and it’s coming soon to Valley Children’s, ...